Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: A population-based study

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1574-1579

  Tsai, H T ^a   Marshall, J L ^b   Weiss, S R ^c,d   Huang, C Y ^e   Warren, J L ^f   Freedman, A N ^f   Fu, A Z ^a   Sansbury, L B ^f   Potosky, A L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adverse events; Arterial thromboembolic events; Bevacizuma; Cardiac death; Congestive heart failure

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

AGED; ARTERIAL THROMBOEMBOLISM; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; FEMALE; HEART DEATH; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84878449640     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt019     Document Type: Article

References (33)

1. WHO. http://globocan.iarc.fr/factsheets/cancers/colorectal.asp. 2011 (14 December 2012, date last accessed).
2. Edwards BK, Howe HL, Ries LA et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer 2002; 94: 2766-2792.
3. Gibson T, Ranganthan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 29-31.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Saltz LB, Meropol N, Loehrer PS et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
6. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
7. Galfrascoli E, Piva S, Cinquini M et al. Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis 2011; 43: 286-294.
8. Kabbinavar FF, Hambleton J, Mass RD et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-3712.
9. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
10. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
11. Shamloo BK, Chhabra P, Freedman AN et al. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. Drug Saf 2012; 35: 507-518.
12. Robinson ES, hanakin EV, Choueiri TK et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56: 1131-1136.
13. Robinson ES, Khankin EV, Karumanchi SA et al. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010; 30: 591-601.
14. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
15. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385-3390.
16. Kabbinavar FF, Hurwitz HI, Yi J et al. Addition of bevacizumab to fluorouracilbased first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205.
17. Meyerhardt JA, Li L, Sanoff HK et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer.J Clin Oncol 2012; 30: 608-615.
18. Tebbutt NC, Murphy F, Zannino D et al. Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Ann Oncol 2011; 22: 1834-1838.
19. Warren JL, Klabunde CN, Schrag D et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40: IV-3-IV-18.
20. Virnig BA, Warren JL, Cooper GS et al. Studying radiation therapy using SEERMedicare- linked data. Med Care 2002; 40: IV-49-IV-54.
21. Klabunde CN, Potosky AL, Legler JM et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267.
22. Krieger N, van den Eeden SK, Zava D et al. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: a study of white, black, and Asian women in the San Francisco bay area. Ethn Dis 1997; 7: 137-149.
23. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992; 82: 703-710.
24. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
25. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 757-763.
26. Sturmer T, Schneeweiss S, Brookhart MA et al. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal anti-inflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005; 161: 891-898.
27. Kurth T, Walker AM, Glynn RJ et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006; 163: 262-270.
28. Ranpura V, Hapani S, Chuang J et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49: 287-297.
29. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-581.
30. Meyer T, Robles-Carrillo L, Robson T et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009; 7: 171-181.
31. Yang R, Thomas G, Bunting S et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performaces. J Cardiovasc Pharmacol 1996; 27: 838-844.
32. Cassidy J, Saltz LB, Giantonio BJ et al. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 2010; 136: 737-743.
33. Birman-Deych E, Waterman AD, Yan Y et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. MedCare 2005; 43: 480-4